In June, Chinese regulators approved the world’s first CAR-T cell therapy for solid tumour cancers, developed by a drug company based in Shanghai. One month later, at a hospital in the city, a New Zealander with advanced cancer of the stomach and small intestine became the first international patient to receive the breakthrough treatment. Chimeric antigen receptor T-cell therapy, to give it its full name, is a cutting-edge treatment that, until then, had only been approved to treat blood…

From China - South China Morning Post via This RSS Feed.